Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon L Croft

Showing results (31-40 of 143) with videos related to

Pageof 15
Sort By:
Bioorganic & Medicinal Chemistry|January 30, 2017
Antiprotozoal glutathione derivatives with flagellar membrane binding activity against T. brucei rhodesienseSylvie Daunes, Vanessa Yardley, Simon L Croft, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2011
In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovaniKarin Seifert, Jane Munday, Tahmina Syeda, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 20, 2003
Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasisAnjan Nan, Simon L Croft, Vanessa Yardley, et al.
Expert Review of Anti-Infective Therapy|August 4, 2011
Developing novel strategies to prevent parasitic infectionsHenry M Staines, Simon L Croft, Paul D Horrocks
The Journal of Antimicrobial Chemotherapy|February 24, 2016
Drug permeation and barrier damage in Leishmania-infected mouse skinKatrien Van Bocxlaer, Vanessa Yardley, Sudaxshina Murdan, et al.
Antimicrobial Agents and Chemotherapy|June 10, 2015
Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidateKarin Seifert, Christiane Juhls, Francisco J Salguero, et al.
Current Opinion in Infectious Diseases|November 14, 2012
Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasisAbeer H A Mohamed-Ahmed, Stephen Brocchini, Simon L Croft
BMJ (Clinical Research Ed.)|February 15, 2003
Leishmaniasis: new approaches to disease controlClive R Davies, Paul Kaye, Simon L Croft, et al.
The Journal of Pharmacy and Pharmacology|May 28, 2016
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse modelKatrien Van Bocxlaer, Vanessa Yardley, Sudaxshina Murdan, et al.
The Journal of Pharmacy and Pharmacology|July 29, 2006
In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasisTracy Garnier, Marc B Brown, M Jayne Lawrence, et al.
Pageof 15

Showing results (31-40 of 143) with videos related to

Sort By:
Pageof 15
Bioorganic & Medicinal Chemistry|January 30, 2017
Antiprotozoal glutathione derivatives with flagellar membrane binding activity against T. brucei rhodesienseSylvie Daunes, Vanessa Yardley, Simon L Croft, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2011
In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovaniKarin Seifert, Jane Munday, Tahmina Syeda, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 20, 2003
Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasisAnjan Nan, Simon L Croft, Vanessa Yardley, et al.
Expert Review of Anti-Infective Therapy|August 4, 2011
Developing novel strategies to prevent parasitic infectionsHenry M Staines, Simon L Croft, Paul D Horrocks
The Journal of Antimicrobial Chemotherapy|February 24, 2016
Drug permeation and barrier damage in Leishmania-infected mouse skinKatrien Van Bocxlaer, Vanessa Yardley, Sudaxshina Murdan, et al.
Antimicrobial Agents and Chemotherapy|June 10, 2015
Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidateKarin Seifert, Christiane Juhls, Francisco J Salguero, et al.
Current Opinion in Infectious Diseases|November 14, 2012
Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasisAbeer H A Mohamed-Ahmed, Stephen Brocchini, Simon L Croft
BMJ (Clinical Research Ed.)|February 15, 2003
Leishmaniasis: new approaches to disease controlClive R Davies, Paul Kaye, Simon L Croft, et al.
The Journal of Pharmacy and Pharmacology|May 28, 2016
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse modelKatrien Van Bocxlaer, Vanessa Yardley, Sudaxshina Murdan, et al.
The Journal of Pharmacy and Pharmacology|July 29, 2006
In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasisTracy Garnier, Marc B Brown, M Jayne Lawrence, et al.
Pageof 15